Robert W. Baird Increases Astrana Health (NASDAQ:ASTH) Price Target to $86.00

Astrana Health (NASDAQ:ASTH) had its target price upped by Robert W. Baird from $67.00 to $86.00 in a report issued on Wednesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Several other equities analysts also recently weighed in on the company. Truist Financial lifted their target price on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, August 9th. BTIG Research lifted their target price on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. KeyCorp initiated coverage on Astrana Health in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 target price on the stock. Finally, Stifel Nicolaus lifted their target price on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $65.17.

Astrana Health Stock Performance

ASTH stock opened at $40.81 on Wednesday. The company has a market cap of $2.30 billion, a P/E ratio of 31.39, a price-to-earnings-growth ratio of 1.96 and a beta of 1.24. Astrana Health has a 1 year low of $32.04 and a 1 year high of $63.20. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.84. The stock’s fifty day moving average price is $55.04 and its 200-day moving average price is $47.66.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. The firm had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period last year, the business posted $0.47 EPS. On average, equities analysts forecast that Astrana Health will post 1.16 earnings per share for the current year.

Institutional Investors Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC bought a new stake in Astrana Health during the third quarter valued at about $4,457,000. State Street Corp bought a new stake in shares of Astrana Health in the third quarter worth about $91,966,000. Stifel Financial Corp bought a new stake in shares of Astrana Health in the third quarter worth about $800,000. QSV Equity Investors LLC bought a new stake in shares of Astrana Health in the third quarter worth about $1,715,000. Finally, Quarry LP bought a new stake in shares of Astrana Health in the third quarter worth about $77,000. 52.77% of the stock is owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.